Related Experiment Videos
Hearing loss--risk factor for cisplatin ototoxicity? Observations
J D Durrant1, G Rodgers, E N Myers
1Department of Otolaryngology, University of Pittsburgh, PA.
The American Journal of Otology
|September 1, 1990
Summary
Cisplatin chemotherapy can cause hearing loss (ototoxicity). However, this study suggests that patients with prior hearing loss do not face a higher risk of developing cisplatin-induced ototoxicity.
Area of Science:
- Oto-oncology
- Clinical pharmacology
- Audiology
Background:
- Cisplatin chemotherapy is a known cause of ototoxicity.
- The impact of pre-existing hearing loss on cisplatin ototoxicity risk is debated.
Purpose of the Study:
- To investigate whether pretreatment hearing loss influences the risk of cisplatin-induced ototoxicity.
- To evaluate the emerging consensus regarding this patient population.
Main Methods:
- A preliminary study was conducted.
- A small sample from the patient population was analyzed.
Main Results:
- Findings support the emerging consensus.
- Pretreatment hearing loss did not appear to increase the risk of cisplatin ototoxicity in this cohort.
Conclusions:
- Pre-existing hearing loss may not elevate the risk of cisplatin-induced ototoxicity.
- Further research with larger cohorts is warranted to confirm these preliminary findings.